Am BioPark 13
93053 Regensburg, de
+49 (941) 6309197-85
T-Track® CMV is a Highly Sensitive Immune-Monitoring Tool for Risk Stratification of Renal Transplant Recipients
Lophius Biosciences GmbH today announced the publication of a peer-reviewed scientific paper covering the company's CE-marked in vitro diagnostic test T-Track® CMV in a clinical study with kidney transplant patients
In this prospective longitudinal multicenter study, 86 kidney transplant recipients were followed over 6 months post-transplantation. CMV-specific cell-mediated immunity was monitored using T-Track® CMV, in parallel to the assessment of CMV viral load and of clinical complications. This study demonstrated the capability of T-Track® CMV not only to measure CMV-specific cell-mediated immunity in immunocompromised patients with high sensitivity (with 88-92% positive tests in patients under immunosuppressive treatment, compared to 95% before transplantation), but also to monitor changes in the patients’ CMV-specific immune status following the administration of immunosuppressive drugs. In addition, T-Track® CMV test results (in response to one of the antigens provided in the IVD kit) were significantly higher in patients with a protective immunity, compared to patients requiring antiviral treatment, highlighting the potential predictive value of the assay.
“The recent publication nicely shows that T-Track® CMV is a valuable tool for the risk stratification of transplant patients and gives an outlook towards its ability to support personalized CMV management. Together with results of on-going clinical studies in allogeneic hematopoietic stem cell and solid-organ transplant recipients we are looking forward to broaden the routine use of our test and making the clinical advantages available to a large number of transplant patients”, said Bernd Merkl, CEO & Managing Director of Lophius Biosciences GmbH.
1)Banas et al. (2017). Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-speciﬁc cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int. doi: 10.1111/tri.13110.
Background CMV, CMV-specific cell-mediated immunity & T-Track® CMV
The replication of CMV, with a high seroprevalence in the human population of 30-90%, is efficiently controlled in healthy individuals by the immune system primarily via cell-mediated immunity. To avoid uncontrolled CMV replication, immunosuppressed patients like transplant recipients are treated with antiviral medication either prophylactically in the first months after transplantation or preemptively based on CMV viral load measurement. However, optimal duration of either prophylaxis or of virological monitoring is not well defined. In the current setting, assessment of CMV-specific immunity and the ability of immunosuppressed patients to control virus replication via their immune system are not taken into consideration. On the one hand this may result in overtreatment of patients with reconstituted and protective CMV immunity. Avoiding unnecessary antiviral treatment would prevent unwanted side effects for the patients and increased costs for the healthcare system. On the other hand it may expose patients with delayed immune reconstitution to higher risk for CMV disease. Therefore, it is equally important to identify these patients with CMV-specific immunity monitoring.
By measuring CMV-specific cell-mediated immunity, T-Track® CMV adds an additional dimension to anti-CMV treatment decision-making, complementing the currently used viral load tests. The close monitoring of CMV-specific immunity using T-Track® CMV together with CMV viral load measurement has the potential to improve risk stratification of patients and to help clinicians in their decision to start, discontinue or adjust antiviral treatment.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.